Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-04-06
DOI
10.1111/dom.14394
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual glucagon‐like peptide‐1 receptor/glucagon receptor agonist SAR425899 improves beta‐cell function in type 2 diabetes
- (2019) Roberto Visentin et al. DIABETES OBESITY & METABOLISM
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
- (2016) Matthias H. Tschöp et al. Cell Metabolism
- Hyperglucagonemia Mitigates the Effect of Metformin on Glucose Production in Prediabetes
- (2016) Adam R. Konopka et al. Cell Reports
- Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
- (2015) V. Salem et al. DIABETES OBESITY & METABOLISM
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists
- (2015) Brian Finan et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- GLP-1 based therapeutics: simultaneously combating T2DM and obesity
- (2015) Kristy M. Heppner et al. Frontiers in Neuroscience
- The Oral Minimal Model Method
- (2014) C. Cobelli et al. DIABETES
- Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study
- (2014) Gonzalo Díaz-Soto et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Global estimates of diabetes prevalence for 2013 and projections for 2035
- (2013) L. Guariguata et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
- (2011) Christoph Kapitza et al. ADVANCES IN THERAPY
- Understanding Equivalence and Noninferiority Testing
- (2010) Esteban Walker et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- The metabolic actions of glucagon revisited
- (2010) Kirk M. Habegger et al. Nature Reviews Endocrinology
- The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies
- (2009) L. Blonde et al. DIABETES OBESITY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More